Background
==========

Lung cancer is one of the most lethal and most common malignant tumors in the world. The incidence of non-small cell lung cancer (NSCLC) in lung cancer overall incidence is about 80%, and it is the main cause of cancer-related deaths in China \[[@b1-medscimonit-26-e923624]\]. Despite advances in treatment options, including radiation, surgery, targeted therapies, and chemotherapy, prognosis remains poor due to the presence of locally advanced or extensively metastatic tumors at diagnosis in most patients \[[@b2-medscimonit-26-e923624]\]. Therefore, scientists are persistently looking for novel drugs to improve the effectiveness of NSCLC treatment.

Traditional Chinese medicines (TCMs), unique biomedical and pharmaceutical resources have been widely used in the prevention and treatment of NSCLC \[[@b3-medscimonit-26-e923624]--[@b5-medscimonit-26-e923624]\]. Artemisia annua is an ancient antipyretic traditional Chinese medicine, which is used as tea or press juice to treat malaria. Since 2015 when the Nobel Prize in Physiology or Medicine was conferred to a Chinese scientist Youyou Tu, Artemisia annua has drawn worldwide attention \[[@b6-medscimonit-26-e923624]\]. Artemisia annua and its derivatives have been shown to have the anti-cancer activity *in vitro* and *in vivo* \[[@b4-medscimonit-26-e923624]--[@b6-medscimonit-26-e923624]\]. Mechanisms for anti-cancer activity of Artemisia annua rely mainly on the generation of reactive oxygen species (ROS) resulting from the interaction of the endoperoxide bridge with either free ferrous iron or heme iron \[[@b7-medscimonit-26-e923624],[@b8-medscimonit-26-e923624]\]. Increased requirements for iron in cancer cells and higher intake of iron through transferrin receptors, typically upregulates in cancer cells, making them more susceptible to damage by ROS from an iron-catalyzed reaction with Artemisia annua \[[@b9-medscimonit-26-e923624]--[@b11-medscimonit-26-e923624]\]. Some fundamental research studies have shown that Artemisia annua possesses qualities of a novel therapeutic for patients with NSCLC \[[@b12-medscimonit-26-e923624],[@b13-medscimonit-26-e923624]\]. In addition, Artemisia annua and its derivatives also exert synergistic anti-tumor effects on NSCLC with a wide array of clinically established drugs \[[@b14-medscimonit-26-e923624]--[@b16-medscimonit-26-e923624]\]. However, Artemisia annua contains hundreds of ingredients; its active ingredients, targets, and mechanism of anti-NSCLC effects have not been apparent.

Due to the multi-chemical components, multi-pharmacological effects, and multi-action targets of TCM in disease treatment, it is difficult for traditional research methods to explain its mechanism of action adequately \[[@b3-medscimonit-26-e923624],[@b6-medscimonit-26-e923624]\]. However, in recent years, network pharmacology generated by the combination of bioinformatics and pharmacology can clarify the principle of action of these herbs \[[@b17-medscimonit-26-e923624],[@b18-medscimonit-26-e923624]\]. Therefore, we used the network pharmacology method to study the mechanism and material basis of Artemisia annua treatment of NSCLC to provide a new theoretical basis and direction for the systematic development of Artemisia annua.

Material and Methods
====================

Database and software
---------------------

The databases involved in this study were the following: Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP, *<http://tcmspw.com/tcmsp.php>*), PubChem (*<http://pubchem.ncbi.nlm.nih.gov>*), Unipot (*<https://www.uniprot.org>*), STRING (*<https://string-db.org/>*), National Center for Biotechnology Information (NBCI) (*<https://www.ncbi.nlm.nih.gov/>*), and The Cancer Genome Atlas (TCGA) (*<https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga>*). The data analysis software includes Cytoscape 3.7.2 (plug-ins ClueGo 2.5.2 and CluePedia 1.5.5), discovery studio, and Venn diagrams (OmicShare tools).

Screening the active ingredients of Artemisia annua and predicting the component-targets
----------------------------------------------------------------------------------------

All the active ingredients of Artemisia annua were collected from the TCMSP platform, and the screening conditions were based on drug-likeness (DL) ≥0.18 and oral bioavailability (OB) ≥30%. Enter the active ingredients into PubChem to search for the corresponding molecular structure and record the corresponding PubChem CID. Then, based on TCMSP database, the potential targets of the active components were matched one by one, and then the target protein and gene information were corrected through UniProt database to select the object of "Homo sapiens," which is the prediction target of the main active ingredients of Artemisia annua.

Seeking out NSCLC-related targets
---------------------------------

With "Non-small-cell lung carcinoma" as the keywords, NBCI (*<https://www.ncbi.nlm.nih.gov/>*) and TCGA (*<https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga>*) were used to search and screen the known disease-targets for the subsequent study, and the repeated targets in the search results were discarded. UniProtKB (*<http://www.uniprot.org/>*) was used to get the standard targets' names with the organism selected as "homo sapiens." Then, the predicted targets of Artemisia annua primary active ingredients and NSCLC related targets were intersected, and the Wayne map was drawn to extract common target genes.

Construction of a protein--protein interaction (PPI) network
------------------------------------------------------------

The common target genes were uploaded to the STRING platform to obtain protein interaction data. Then use Cytoscape software to establish and analyze the protein-protein interaction (PPI) network, and classify according to the MCODE algorithm, which is a method to automatically find molecular complexes in large protein interaction networks \[[@b19-medscimonit-26-e923624]\]. The size and color depth of the nodes were set according to the degree, that is, the larger the node was, the higher the degree of the target gene corresponding to the darker the color was. The thickness of the edge expressed the score of the relationship value between the 2 target genes, that is, the higher the combination score, the thicker the line of the edge.

Gene Ontology (GO) biological function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis
---------------------------------------------------------------------------------------------------------------------

Using the ClueGo and CluePedia plug-ins on the Cytoscape software, and using *P*\<0.05 as the screening condition for statistical differences, Gene Ontology (GO) biological function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the potential targets of Artemisia annua against NSCLC were performed. Furthermore, the main signal pathway and the biological process involved in the pharmacological action of Artemisia annua against NSCLC were obtained, and the topological network diagram of the active component target genes of Artemisia annua was constructed.

Results
=======

Active ingredients and target selection of Artemisia annua
----------------------------------------------------------

After screening, a total of 19 main active ingredients were included in the study, target prediction was carried out for these 19 ingredients, and 510 targets were extracted after de-duplication, as shown in [Table 1](#t1-medscimonit-26-e923624){ref-type="table"}.

Screening of NSCLC targets
--------------------------

The database of NCBI and TCGA were used to retrieve 1520 and 1042 NSCLC related targets respectively, and then the human gene name transformation was carried out through the UniProt database. The NCBI as aforementioned related target genes and 185 predicted target genes, were input into Venn Diagrams (OmicShare tools) software for intersection and construction of Venn diagrams as shown in [Figure 1](#f1-medscimonit-26-e923624){ref-type="fig"}. There were 40 common target genes, namely Artemisia annua potential anti-NSCLC targets obtained as shown in [Table 2](#t2-medscimonit-26-e923624){ref-type="table"}.

Construction of PPI network
---------------------------

As shown in [Figure 2](#f2-medscimonit-26-e923624){ref-type="fig"}, the aforementioned 40 target genes were uploaded to the STRING platform, and the species was set as "Homo sapiens" and the rest parameters were defaulted to obtain the protein interaction data information; then, they were imported into the software of Cytoscape to draw the PPI network. In the PPI network, 25 nodes (target genes) interact through 412 edges. The area of a node was positively related to the degree of the node that indicates the number of relationships between the node and other nodes in the network. AKT1, MYC, CCND1, VEGFA, JUN, MAPK1, EGFR, and ESR1 have a large node area and can be easily found in the PPI network ([Figure 1](#f1-medscimonit-26-e923624){ref-type="fig"}), and their corresponding degrees were 36, 35, 34, 33, 32, 32, and 31 respectively ([Table 2](#t2-medscimonit-26-e923624){ref-type="table"}).

Construction of anti-NSCLC target network of Artemisia annua active ingredients
-------------------------------------------------------------------------------

We took the 40 common targets as the anti-NSCLC targets of Artemisia annua ([Table 2](#t2-medscimonit-26-e923624){ref-type="table"}), and we import them into Cytoscape 3.7.2 to construct the network diagram of active components and targets of Artemisia annua for NSCLC treatment ([Figure 3](#f3-medscimonit-26-e923624){ref-type="fig"}). The rectangle represents the active ingredient of Artemisia annua for NSCLC treatment, and the ellipse represents the target. The same related biological processes and molecular functions were obtained.

GO biological process analysis
------------------------------

Based on the plug-ins "ClueGo" of Cytoscape software platform, GO biological process enrichment analysis was carried out on the anti-NSCLC target points of Artemisia annua obtained in "2.4", 10 biological processes with *P*\<0.05 were screened, as shown in [Table 3](#t3-medscimonit-26-e923624){ref-type="table"}, and the visualization results are shown in [Figure 4](#f4-medscimonit-26-e923624){ref-type="fig"}. The biological process of Artemisia annua against NSCLC mainly involved the regulation of oxidative stress-induced intrinsic apoptotic signaling pathway, regulation of anoikis, negative regulation of hydrogen peroxide-induced cell death, and DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator. This suggested that the active ingredients of Artemisia annua may act on NSCLC by intervening in the above biological processes.

Enrichment analysis of KEGG signaling pathway
---------------------------------------------

Based on the plug-ins "ClueGo" of Cytoscape software platform, the enrichment analysis of KEGG signal path of Artemisia annua anti-NSCLC target obtained in "2.4" was carried out, and signal paths with *P*\<0.05 were screened, as shown in [Table 4](#t4-medscimonit-26-e923624){ref-type="table"}, and the visualization results are shown in [Figure 5](#f5-medscimonit-26-e923624){ref-type="fig"}. The signal pathways involved in Artemisia annua anti-NSCLC included PI3K/Akt signal pathway, apoptosis, JAK/STAT signal pathway, VEGF signal pathway, etc.

Discussion
==========

The effectiveness of traditional Chinese medicine (TCM) and its derivatives in treating cancer has been more and more affirmed, and it has been widely used in the clinic \[[@b3-medscimonit-26-e923624],[@b20-medscimonit-26-e923624]\]. A large number of clinical studies have reported the beneficial effects of TCM on the survival, immune modulation, and quality of life of cancer patients, which indicates that TCM has a significant therapeutic value and represents an excellent resource for drug discovery \[[@b21-medscimonit-26-e923624],[@b22-medscimonit-26-e923624]\]. As we all know, TCM contains complex ingredients to enhance their therapeutic effects or reduce their toxicity. Therefore, it is crucial to find out and make rational use of the characteristics of TCM with multi-components, multi-targets, and multi-channels.

Network pharmacology looks at biological networks, analyzing the links among drugs, targets, and diseases in these networks, which provides a comprehensive and systematic study with the characteristics of a holistic view; the holistic view is the main feature of traditional Chinese medicine. Therefore, network pharmacology can be used to explore the synergistic effects of various targets and pathways of traditional Chinese medicine \[[@b17-medscimonit-26-e923624],[@b18-medscimonit-26-e923624]\]. Artemisia annua and its derivatives have been found to have anti-cancer activity *in vitro* and *in vivo* \[[@b4-medscimonit-26-e923624],[@b22-medscimonit-26-e923624]--[@b24-medscimonit-26-e923624]\]. Artemisia annua and its derivatives are not only widely used for the treatment of various tumors, but also the prevention of tumors \[[@b6-medscimonit-26-e923624],[@b23-medscimonit-26-e923624]--[@b25-medscimonit-26-e923624]\]. Artemisia annua and its derivatives also exert synergistic anti-tumor effects with a wide array of clinically established drugs \[[@b26-medscimonit-26-e923624]--[@b28-medscimonit-26-e923624]\]. However, the target and mechanism of Artemisia annua against NSCLC have not been apparent.

In this study, 19 active ingredients of Artemisia annua were screened out via TCMSP database as potential targets. These potential ingredients were as follows: Luteolin, Quercetin, Isorhamnetin, Sitosterol, Kaempferol, Stigmasterol, EUPATIN, Tamarixetin, Patuletin, Areapillin, Artemetin, Skrofulein, Cirsiliol, vitexin_qt, DMQT, \[(2S)-2-\[\[(2S)-2-(benzoyl amino)-3-phenylpropanoyl\]amino\]-3-phenylpropyl\] acetate, 6,8-di-c-glucosylapigenin_qt, Artemisinin, and deoxyartemisinin. Then, we screened out 40 common target genes that might have potential anti-NSCLC function by the integration of a multi-source database.

In networks, the basic unit is a node, which can be a disease, target, or a drug; the connection between any 2 nodes is termed an edge. A particular group of related nodes is called a module and the connection between any 2 modules is termed a bridge. The degree and hubs are promising targets or parameters for drug discovery, and the complex relationships among diseases, targets, and drugs in network pharmacology can thus be visualized. In this study, we established a visual PPI network to analyze the interaction between these targets, and we based on the matching results between the potential targets of Artemisia annua and NSCLC tumor targets, screen the central targets by topology. We found that AKT1, MYC, CCND1, VEGFA, JUN, MAPK1, EGFR, ESR1 nodule area, and corresponding degree values were large, and could be easily found in the PPI network. We also found that AKT1, MYC, CCND1, VEGFA, JUN, MAPK1, EGFR, ESR1, and other genes are involved in 2 or more pathways as crosstalk genes, suggesting that these genes or pathways may be the main targets of Artemisia annua against NSCLC. As we all know, these pathways and genes are mainly involved in tumor cell proliferation, apoptosis, cell cycle regulation, epithelial-stromal transformation, angiogenesis, tumor invasion and metastasis, tumor signal transduction, immune regulation, drug resistance and other critical biological processes \[[@b27-medscimonit-26-e923624]--[@b30-medscimonit-26-e923624]\]. More importantly, these pathways and genes might cooperate in promoting metastasis of NSCLC through crosstalk between cancer and immune microenvironment \[[@b29-medscimonit-26-e923624]--[@b31-medscimonit-26-e923624]\].

Furthermore, GO enrichment analysis was used to analyze the biological process of Artemisia annua's potential anti-NSCLC targets. We found that Artemisia annua's anti-NSCLC target involved 10 biological processes, including the regulation of oxidative stress-induced intrinsic apoptotic signaling pathway, regulation of mitochondrial depolarization, negative regulation of hydrogen peroxide-induced cell death, regulation of anoikis, cytoplasmic sequestering of NF-kappaB, regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway, and monocyte differentiation. These biological processes are related to the occurrence of NSCLC, reflecting the characteristics of Artemisia annua as a multi-component, multi-target, and multi-channel treatment of NSCLC.

According to the analysis of KEGG signal pathway enrichment, there were 68 signal pathways related to the effect of Artemisia annua on NSCLC, including PI3K, Akt, JAK stat, erbB, FOXO, p53, HIF-1, toll-like receptor, TNF, and VEGF, which are strictly related to the pathogenesis of cancer. According to reports, inhibition of NSCLC mediated by IFN-g is regulated by PI3K-Akt signal transduction, and the inhibition of PI3K can downregulate the expression of PD-L1 and enhance the anti-tumor effect of IFN-g, which indicates that the inhibition of PI3K can maximize the anti-tumor impact mediated by IFN-g \[[@b32-medscimonit-26-e923624]\]. Xu et al. found that the expression of JAK2 gene was upregulated in cancer tissues, and was related to lymph node metastasis, and upregulated expression of JAK2 could enhance the ability of tumor cell proliferation, metastasis, and invasion. In contrast, downregulated expression of JAK2 had the opposite effect \[[@b33-medscimonit-26-e923624]\]. Kachroo et al. found that interleukin-27 (IL-27) could induce epithelial cell transformation and inhibit the generation of angiogenic factors through STAT1 in NSCLC cell lines \[[@b34-medscimonit-26-e923624]\]. Another study found that STAT3 could induce MDSCs and macrophages to kill CD4+ and CD8+T cells, induce the growth and inhibition of dendritic cells (DCS), and make macrophages differentiate from M1 to M2 in lung tumorigenesis, thus promoting the development of lung cancer \[[@b35-medscimonit-26-e923624]\]. Quercetin is the active ingredient in Artemisia annua. It exerts anticancer effects on cancer cells and tumors by regulating PI3K/Akt/mTOR, Wnt/b-catenin, and MAPK/ERK1/2 pathways. Quercetin promotes the loss of cell viability, apoptosis, and autophagy in cancer by reducing the stability of b-catenin and HIF-1a, inducing caspase-3 activation and inhibiting Akt, mTOR, and ERK phosphorylation \[[@b36-medscimonit-26-e923624]\]. Kaempferol is the active ingredient that also inhibits apoptosis, autophagy, and proliferation in NSCLC cells, which might function through the upregulation of PTEN and inactivation of the PI3K/AKT pathway \[[@b37-medscimonit-26-e923624]\]. Therefore, it is speculated that Artemisia annua might exert an anti-NSCLC effect by acting on the related signaling pathways or targets.

Although the present research revealed the mechanism of Artemisia annua in the treatment of NSCLC from the perspective of network pharmacology, it still has several limitations. The main limitation of this study is the lack of experimental verification, which will be further expanded in future research.

Conclusions
===========

In summary, bioinformatics and network pharmacology analysis reveals the molecular biological mechanism of Artemisia annua anti-NSCLC via multiple active components, multi-channels, and multi-targets. The targets identified included AKT1, MYC, CCND1, VEGFA, JUN, MAPK1, EGFR, ESR1, et al. in the network of AN and NSCLC, indicating potential as therapeutic biomolecules for treating NSCLS. It is suggested that Artemisia annua might be developed as a promising anti-NSCLC drug.
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###### 

Main active components of artemisia annua.

  TCMSP ID    PubChem CID   compound                                                                                 Target number
  ----------- ------------- ---------------------------------------------------------------------------------------- ---------------
  MOL000006   5280445       Luteolin                                                                                 57
  MOL000098   5280343       Quercetin                                                                                154
  MOL000354   5281654       Isorhamnetin                                                                             37
  MOL000359   12303645      Sitosterol                                                                               3
  MOL000422   5280863       Kaempferol                                                                               63
  MOL000449   5280794       Stigmasterol                                                                             31
  MOL002235   5317287       EUPATIN                                                                                  16
  MOL004083   5281699       Tamarixetin                                                                              15
  MOL004112   5281678       Patuletin                                                                                11
  MOL004609   158311        Areapillin                                                                               17
  MOL005229   5320351       Artemetin                                                                                23
  MOL007274   188323        Skrofulein                                                                               11
  MOL007401   160237        Cirsiliol                                                                                10
  MOL007404   N/A           Vitexin_qt                                                                               15
  MOL007412   5281603       DMQT                                                                                     10
  MOL007415   10026486      \[(2S)-2-\[\[(2S)-2-(benzoylamino)-3-phenylpropanoyl\]amino\]-3-phenylpropyl\] acetate   5
  MOL007423   N/A           6,8-di-c-glucosylapigenin_qt                                                             16
  MOL007424   N/A           Artemisinin                                                                              15
  MOL007426   N/A           Deoxyartemisinin                                                                         1

###### 

The potential anti-non-small cell lung cancer target of artemisia annua.

  UniprotID   Target protein                                                  Name     Degree
  ----------- --------------------------------------------------------------- -------- --------
  P31749      RAC-alpha serine/threonine-protein kinase                       AKT1     36
  P01106      Myc proto-oncogene protein                                      MYC      35
  P15692      Vascular endothelial growth factor A                            VEGFA    34
  P24385      G1/S-specific cyclin-D1                                         CCND1    34
  P05412      Transcription factor AP-1                                       JUN      33
  P28482      Mitogen-activated protein kinase 1                              MAPK1    32
  P00533      Epidermal growth factor receptor                                EGFR     32
  P03372      Estrogen receptor                                               ESR1     31
  Q07817      Bcl-2-like protein 1                                            BCL2L1   28
  P04626      Receptor tyrosine-protein kinase erbB-2                         ERBB2    28
  Q16665      Hypoxia-inducible factor 1-alpha                                HIF1A    27
  P38936      Cyclin-dependent kinase inhibitor 1                             CDKN1A   26
  Q07820      Induced myeloid leukemia cell differentiation protein Mcl-1     MCL1     26
  Q00987      E3 ubiquitin-protein ligase Mdm2                                MDM2     26
  O15519      Caspase-8                                                       CASP8    25
  P37231      Peroxisome proliferator activated receptor gamma                PPARG    22
  P42224      Signal transducer and activator of transcription 1-alpha/beta   STAT1    22
  P09874      Poly \[ADP-ribose\] polymerase 1                                PARP1    21
  P22301      Interleukin-10                                                  IL10     20
  P06400      Retinoblastoma-associated protein                               RB1      19
  P35968      Vascular endothelial growth factor receptor 2                   KDR      18
  P49841      Glycogen synthase kinase-3 beta                                 GSK3B    17
  P04049      RAF proto-oncogene serine/threonine-protein kinase              RAF1     17
  O14757      Serine/threonine-protein kinase Chk1                            CHEK1    17
  P08581      Hepatocyte growth factor receptor                               MET      17
  P25963      NF-kappa-B inhibitor alpha                                      NFKBIA   15
  O96017      Serine/threonine-protein kinase Chk2                            CHEK2    15
  P01344      Insulin-like growth factor II                                   IGF2     15
  P10415      Apoptosis regulator Bcl-2                                       BCL2     14
  Q13950      Runt-related transcription factor 2                             RUNX2    14
  O14920      Inhibitor of nuclear factor kappa-B kinase subunit beta         IKBKB    13
  Q07812      Apoptosis regulator                                             BAX      13
  P21860      Receptor tyrosine-protein kinase erbB-3                         ERBB3    13
  P11387      DNA topoisomerase 1                                             TOP1     13
  Q16236      Nuclear factor erythroid 2-related factor 2                     NFE2L2   12
  Q9H3D4      Cellular tumor antigen p53                                      TP63     11
  P02452      Collagen alpha-1 (I) chain                                      COL1A1   11
  P19793      Retinoic acid receptor RXR-alpha                                RXRA     9
  Q15596      Nuclear receptor coactivator 2                                  NCOA2    7
  P06213      Insulin receptor                                                INSR     6

###### 

The biological process of artemisia annua on non-small cell lung cancer target.

  *P*-value   Description                                                                                                       Group genes
  ----------- ----------------------------------------------------------------------------------------------------------------- ---------------------------
  6.51E-06    Regulation of oxidative stress-induced intrinsic apoptotic signaling pathway                                      AKT1, MCL1, NFE2L2, PARP1
  8.93E-05    Regulation of mitochondrial depolarization                                                                        BCL2, KDR, PARP1
  1.85E-04    Cellular response to vitamin                                                                                      COL1A1, MDM2, PPARG
  1.85E-04    Negative regulation of hydrogen peroxide-induced cell death                                                       IL10, MET, NFE2L2
  1.85E-04    Regulation of anoikis                                                                                             BCL2, CHEK2, MCL1
  3.91E-04    Cytoplasmic sequestering of NF-kappaB                                                                             IL10, NFKBIA
  4.02E-04    Regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway                               MCL1, PARP1
  8.23E-04    Monocyte differentiation                                                                                          JUN, PPARG
  1.27E-03    Ositive regulation of glycogen biosynthetic process                                                               AKT1, INSR
  1.57E-03    DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator   CDKN1A, CHEK2

###### 

Enrichment analysis of KEGG signal pathway of artemisia annua anti-small cell lung cancer targets (top 20).

  KEGG ID       Pathway                                    *P*-value   Group genes
  ------------- ------------------------------------------ ----------- ---------------------------------------------------------------------------------------------------------------------------------------
  KEGG: 04151   PI3K-Akt signaling pathway                 3.28E-17    AKT1, BCL2, BCL2L1, CCND1, CDKN1A, COL1A1, EGFR, ERBB2, ERBB3, GSK3B, IGF2, IKBKB, INSR, KDR, MAPK1, MCL1, MDM2, MET, MYC, RAF1, RXRA
  KEGG: 04210   Apoptosis                                  4.69E-11    AKT1, BAX, BCL2, BCL2L1, CASP8, IKBKB, JUN, MAPK1, MCL1, NFKBIA, PARP1, RAF1
  KEGG: 04012   ErbB signaling pathway                     2.45E-10    AKT1, CDKN1A, EGFR, ERBB2, ERBB3, GSK3B, JUN, MAPK1, MYC, RAF1
  KEGG: 04115   p53 signaling pathway                      1.76E-09    BAX, BCL2, BCL2L1, CASP8, CCND1, CDKN1A, CHEK1, CHEK2, MDM2
  KEGG: 04625   C-type lectin receptor signaling pathway   1.79E-09    AKT1, CASP8, IKBKB, IL10, JUN, MAPK1, MDM2, NFKBIA, RAF1, STAT1
  KEGG: 04510   Focal adhesion                             3.56E-09    AKT1, BCL2, CCND1, COL1A1, EGFR, ERBB2, GSK3B, JUN, KDR, MAPK1, MET, RAF1
  KEGG: 04630   JAK-STAT signaling pathway                 6.86E-09    AKT1, BCL2, BCL2L1, CCND1, CDKN1A, EGFR, IL10, MCL1, MYC, RAF1, STAT1
  KEGG: 04068   FoxO signaling pathway                     1.72E-08    AKT1, CCND1, CDKN1A, EGFR, IKBKB, IL10, INSR, MAPK1, MDM2, RAF1
  KEGG: 04218   Cellular senescence                        1.05E-07    AKT1, CCND1, CDKN1A, CHEK1, CHEK2, MAPK1, MDM2, MYC, RAF1, RB1
  KEGG: 04066   HIF-1 signaling pathway                    6.47E-07    AKT1, BCL2, CDKN1A, EGFR, ERBB2, HIF1A, INSR, MAPK1
  KEGG: 04110   Cell cycle                                 2.95E-06    CCND1, CDKN1A, CHEK1, CHEK2, GSK3B, MDM2, MYC, RB1
  KEGG: 04620   Toll-like receptor signaling pathway       1.28E-05    AKT1, CASP8, IKBKB, JUN, MAPK1, NFKBIA, STAT1
  KEGG: 04380   Osteoclast differentiation                 4.29E-05    AKT1, IKBKB, JUN, MAPK1, NFKBIA, PPARG, STAT1
  KEGG: 04657   IL-17 signaling pathway                    8.36E-05    CASP8, GSK3B, IKBKB, JUN, MAPK1, NFKBIA
  KEGG: 04215   Apoptosis                                  2.21E-04    BAX, BCL2, BCL2L1, CASP8
  KEGG: 04520   Adherens junction                          2.65E-04    EGFR, ERBB2, INSR, MAPK1, MET
  KEGG: 04658   Th1 and Th2 cell differentiation           7.11E-04    IKBKB, JUN, MAPK1, NFKBIA, STAT1
  KEGG: 04064   NF-kappa B signaling pathway               7.37E-04    BCL2, BCL2L1, IKBKB, NFKBIA, PARP1
  KEGG: 04370   VEGF signaling pathway                     1.31E-03    AKT1, KDR, MAPK1, RAF1
  KEGG: 04340   Hedgehog signaling pathway                 6.15E-03    BCL2, CCND1, GSK3B
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